Learn details of the Advances in Onychomycosis Treatment Market Forecast and Segments, 2016-2026

Onychomycosis is a nail infection caused by fungus–Trichophyton rubrum. Currenty, around 2-3% of the U.S. population are suffering from onynchomycosis. Onychomycosis is majorly four types which include distal subungual onychomycosis, proximal subungual onychomycosis, and white superficial onychomycosis and candida infections of the nail. Among these, subungual onychomycosis has the highest prevalence rate and its incidence rate is increasing at a significant rate owing to rise in geriatrics population. People with diabetes, HIV and cardiac disease are more susceptible to Onychomycosis.

Nail paint having dissolved drugs and oral drugs such as ciclopirox, griseofulvin, itraconazole, terbinafine are commonly used to treat onychomycosis.

A sample of this report is available upon request @  https://www.futuremarketinsights.com/reports/sample/rep-gb-1279

Onychomycosis Treatment Market: Drivers and Restraints: Globally onychomycosis treatment market is mainly driven by increased prevalence rate of diabetic patients and geriatric population. Onychomycosis is more prevalent in developed regions as compared to developing regions. This is mainly attributed to high prevalence rate of chronic disorders in developed regions. Though increase in demand for effective treatment of onychomycosis is boosting overall sales of drugs, low healthcare expenditure along with lack of awareness among mass population in developing regions is a key challenge for overall growth of onychomycosis market.

Onychomycosis Treatment Market: Segmentation: Onychomycosis treatment market further segmented into following type:
By Treatment:
Drugs,

Laser Therapy,

Ultrasound Therapy,

By Product Type:

Tablet,

Nail Paint,

Device,

Laser Beam,

Ultrasound,

By Product Type:

Hospital,

Clinics,

Drug store,

Hospital pharmacies,

Onychomycosis Treatment Market: Overview: Increasing healthcare R&D spending along with rise in healthcare expenditure is expected to boost onychomycosismarket. Onychomycosis is expected to witness healthy growth during the forecast period.

Onychomycosis Treatment Market: Region- wise Outlook: The global Onychomycosis Treatment Market is expected to register a healthy CAGR for the forecast period. Depending on geographic regions, global Onychomycosis Treatment Market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, and Asia Pacific excluding Japan, Japan and Middle East & Africa

Geographically, North America dominates the global market for onychomysis treatment due to increasing awareness among people about the onychomycosis infection. Europe holds the second position owing to its large geriatric population. Though North America and Europe are expected to dominate the overall market throughout the forecast period, Asia-pacific is expected to witness fastest growth between 2016 and 2026.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/toc/rep-gb-1279

Onychomycosis Treatment Market: Key Players: Major market players contributing the global market share onychomycosis includes GlaxoSmithKline Pharmaceuticals Limited, Pfizer Inc., Abbott Laboratories, Galaderma, Janssen Global Services, LLC, NuvoLase, Inc,Cutera, Sciton Inc,, Novartis AG, Bristol Meyer Squibb,

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

NY
NY

This release was published on openPR.